Workflow
Base
icon
Search documents
Intro to GraphRAG — Zach Blumenfeld
AI Engineer· 2025-06-30 22:56
[Music] So, as you come in, we have here a server set up with everything you'll need. If you want to follow along, you should have gotten a post-it note. If you don't, just raise your hand and my colleague Alex over here will come find you and we'll provide you with one.Uh, basically what you're going to do is you're just going to go, if you have a number 160 or below, you go to this link here, the QR code on top as well. Um, and if you have a number that's 2011 or above, you go to the second link or the QR ...
X @Andy
Andy· 2025-06-30 15:26
RT BREAD | ∑: (@0xBreadguy)It would appear my morning schedule forced me to miss the actual announcement: Robinhood L2 ala Base.This is:→ Bullish $ETH (as much as a separate chain can be)→ Neutral $ARB (*points to $OP*)The biggest question for me now is who they'll appoint as chain founder.If it's vlad this shit sends. If it's some weirdo who doesn't play in CT then it probably does a Kraken-like move and "meh" ...
X @Bloomberg
Bloomberg· 2025-06-30 15:11
The Iran-Israel war highlighted a critical flaw in shipping's satellite-based systems that makes the industry hauling 80% of global trade vulnerable to mass-jamming https://t.co/v3NwVuTbKz ...
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025
Globenewswire· 2025-06-30 15:05
Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calenda ...
Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?
ZACKS· 2025-06-30 13:31
Core Viewpoint - Vertex Pharmaceuticals has experienced an 8.9% decline in stock price over the past three months, attributed to soft first-quarter results, slower uptake of new drugs, and geopolitical tensions affecting economic growth [1][2][10]. Group 1: Financial Performance - Vertex's CF product sales continue to grow, driven by demand for Trikafta/Kaftrio among younger age groups, although there are concerns about a slight slowdown in sales growth [4]. - The company expects CF sales to grow approximately 8% in 2025, supported by the launch of new products and continued demand for existing therapies [10][24]. - The Zacks Consensus Estimate for 2025 earnings has increased from $17.69 to $17.82 per share over the past 60 days, indicating positive analyst sentiment [22]. Group 2: Product Pipeline and Approvals - Vertex has gained approval for two new products: Journavx, a non-opioid pain medicine, and Alyftrek, a new CF treatment, with expectations for sales to improve in the second half of 2025 [5][10]. - Casgevy, a CRISPR-based therapy for sickle cell disease and beta-thalassemia, is anticipated to ramp up revenues as more patients are treated in approved regions [8][11]. - Vertex's pipeline includes several mid- to late-stage programs targeting various diseases, with four programs in pivotal development and potential regulatory filings expected next year [12][13]. Group 3: Market Position and Competition - Vertex maintains a dominant position in the CF market with minimal competition, which is expected to support continued sales growth despite recent challenges [24]. - The company is addressing concerns about its reliance on the CF franchise for growth by diversifying its product offerings with new therapies [24].
Mercurity Fintech Officially Joins Russell 2000 Index
GlobeNewswire· 2025-06-30 13:00
Inclusion took effect after market close on June 27, strengthening institutional investor access and market visibility New York, NY, June 30, 2025 (GLOBE NEWSWIRE) -- Mercurity Fintech Holding Inc. (the "Company," "we," "us," "our company," or "MFH") (Nasdaq: MFH), a digital fintech group, today announced that it has officially joined the Russell 2000® Index, effective after the U.S. market close on June 27. The inclusion follows MFH's addition to the preliminary reconstitution list announced on May 23, 202 ...
X @Bloomberg
Bloomberg· 2025-06-30 11:31
Ireland should broaden its tax base to ensure its budget protects long-term fiscal stability, the Central Bank of Ireland warned https://t.co/gQSgoijKWh ...
X @Bloomberg
Bloomberg· 2025-06-30 05:10
The Iran-Israel war highlighted a critical flaw in shipping's satellite-based systems that makes the industry hauling 80% of global trade vulnerable to mass-jamming. Read The Big Take: https://t.co/Dl3zBTGdly📷: Clare Louise Jackson/Shutterstock https://t.co/BXvfGleYui ...
X @Cointelegraph
Cointelegraph· 2025-06-29 10:00
🔥 NEW : Redstone reports that up to 30% of the $400T+ global asset base could be tokenized by 2034.Positioning RWAs as a market over 130× larger than today’s ~$3T crypto space. https://t.co/M9TWFd250g ...
X @Cointelegraph
Cointelegraph· 2025-06-28 12:00
⚡️NEW: Vitalik weighs in on token-based UBIs like WLD.“Personally, I do not expect such tokens to be worth anywhere close to enough to pay for a person’s subsistence.” https://t.co/nUg9YCybj7 ...